Article Text

Download PDFPDF
Review: oral and intravaginal agents are equally effective for treatment of uncomplicated vulvovaginal candidiasis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

QUESTION: Are oral and intravaginal antifungal agents equally effective, safe, and cost effective for treatment of uncomplicated vulvovaginal candidiasis (thrush)?

Data sources

Randomised controlled trials (RCTs) published in any language were identified by searching the Cochrane Controlled Trials Register (CENTRAL/CCTR), the Cochrane Collaboration Sexually Transmitted Disease Group Specialised Register of Controlled Trials, EMBASE/Excerpta Medica (1980 to January 2000), and Medline (January 1985 to May 2000). Reference lists of each trial were reviewed and UK manufacturers of antifungal agents were contacted.

Study selection

Trials were selected if they included women ≥16 years of age with mycologically confirmed uncomplicated vulvovaginal candidiasis and they compared ≥1 oral antifungal agent with an intravaginal antifungal agent. Trials were excluded if they included only participants who were HIV positive, immunocompromised, pregnant, breast feeding, or diabetic.

Data extraction

Data were extracted on the type, …

View Full Text


  • Source of funding: Chief Scientist Office, Scottish Executive Health Department UK.

  • For correspondence: Dr M C Watson, Department of General Practice and Primary Care, University of Aberdeen, Westburn Road, Aberdeen AB25 2AY, UK. Fax +44 122 484 0683. m.c.watson{at}